Dendrite Campaign Manager 6.0 Delivers Integrated, Multi-Channel Marketing Capabilities to Pharmaceutical Marketers; Platform E
June 08 2006 - 8:00AM
Business Wire
Dendrite International, Inc. (NASDAQ: DRTE), a leading provider of
pharmaceutical industry solutions, today announced the launch of a
new version of its web based marketing solution, Dendrite Campaign
Manager(TM) 6.0 that enables pharmaceutical companies to deliver
highly targeted, multi-channel marketing campaigns to prescribers
and their patients. These latest advances are possible as a result
of Dendrite's recent acquisition of Optas; an important proof point
of its strategy to expand its marketing solutions offerings, to
equip customers with powerful integrated marketing and sales
campaign capabilities rooted in the deepest understanding of
patient and physician preferences. Campaign Manager 6.0's built-in
functionality enables pharmaceutical marketers to segment and
target their customers, generate lists for execution channels,
create and deploy emails and surveys, and track campaign
effectiveness. The tool's web-based architecture enables marketers
to capture opt-in registration information, track multi-segmented
campaigns and easily view all campaign activity online. New
built-in enhancements to Dendrite Campaign Manager 6.0 include
automated privacy compliance features that shield the
pharmaceutical marketer from inadvertently discovering or
improperly using personally identifiable information during the
design and deployment of their marketing initiatives, and to enable
strict adherence to US-based federal and state regulations,
including HIPAA, CAN SPAM and the even more rigorous European
regulations. "When we added Optas to our portfolio of solutions, we
gave our customers a way to maximize the effectiveness of their
marketing campaigns," said Rick Rose, vice president and general
manager, Dendrite Marketing Solutions. "The release of version 6.0
expands our leadership position in this area and provides a
tremendous asset to our clients as they look to launch and promote
brands on a global basis -- thanks not only to the automation of
complex events that allow for greater efficiencies in program
management, but also, and more importantly, to the powerful
insights obtained through the actionable data derived from this
platform." About Dendrite Founded in 1986, Dendrite International
(NASDAQ: DRTE) enables sales, marketing, clinical and compliance
solutions for the global pharmaceutical industry. The Company's
clients are located in more than 50 countries and include the
world's top 20 pharmaceutical companies. For more information,
please visit www.dendrite.com. Note: Dendrite is a registered
trademark of Dendrite International, Inc. This document may contain
forward-looking statements that may be identified by such
forward-looking terminology as "expect," "believe," "anticipate,"
"will," "intend," "plan," "target," "outlook," "guidance," and
similar statements or variations. Such forward-looking statements
are based on our current expectations, estimates, assumptions and
projections and involve significant risks and uncertainties,
including risks which may result from our dependence on the
pharmaceutical industry; fluctuations in quarterly revenues due to
lengthy sales and implementation cycles for certain of our
solutions; our fixed expenses in relation to fluctuating revenues
and variations in customers' budget cycles; dependence on certain
major customers; changes in demand for our products and services
attributable to any weakness experienced in the economy or mergers,
acquisitions and consolidations in the pharmaceutical industry;
successful and timely development and introduction of new products
and versions; rapid technological changes; increased competition;
international operations; integrating the entities we acquire; our
ability to effectively manage our growth; the protection of our
proprietary technology; our ability to compete in the
Internet-related products and services market; the continued demand
for Internet-related products and services; the ability of our
third party vendors to respond to technological change; our ability
to maintain our relationships with third-party vendors; less
favorable than anticipated results from strategic relationships;
dependence of data solutions on strategic relationships; events
which may affect the U.S. and world economies; and catastrophic
events which could negatively affect our information technology
infrastructure. Other important factors that should be reviewed and
carefully considered are included in the company's 10-K, 10-Qs, and
other reports filed with the SEC. Actual results may differ
materially. The company assumes no obligation for updating any such
forward-looking statements to reflect actual results, changes in
assumptions or other changes affecting such forward-looking
statements.
Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Aug 2023 to Aug 2024